drugset / Trial / NCT01326481
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Phase 1/2
Completed
19 enrolled
Tracon Pharmaceuticals Inc.
Roswell Park Cancer Institute · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent metastatic breast cancer.
Timeline
- Start
- 2011-06
- Primary completion
- 2014-09
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carotuximab | Monoclonal antibody | — | Intravenous |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |